What is the current Guanfacine Hydrochloride Tablets market size?

The Guanfacine Hydrochloride Tablets market size was valued at approximately USD 1.2 billion in 2023, driven by rising hypertension and ADHD treatment demands globally.

What is the expected growth rate in the next five years?

The market is projected to grow at a CAGR of 5.5% from 2024 to 2030, influenced by increased chronic disease prevalence and pediatric healthcare advancements.

What are the key drivers of market expansion?

Drivers include rising hypertension cases, growing ADHD diagnoses, and enhanced pediatric healthcare infrastructure, particularly in emerging economies.

What challenges hinder market growth?

Challenges include adverse drug effects like dizziness, competition from generic alternatives, and regulatory hurdles in new market entries.

Which regions are leading the market?

North America leads the market due to high healthcare expenditure, followed by Europe and Asia-Pacific, driven by aging populations and expanding healthcare access.

Who are the top companies in this market?

Key players include Supernus Pharmaceuticals, Takeda Pharmaceutical, and Mylan N.V., known for innovative formulations and strong distribution networks.

What future opportunities exist for market players?

Emerging markets, over-the-counter drug conversions, and partnerships with telehealth platforms present untapped growth opportunities in the coming decade.

How does technology impact this market?

Advancements in extended-release formulations and digital health tools improve patient adherence, enhancing the Guanfacine Hydrochloride Tablets' therapeutic effectiveness.

What is the regulatory landscape like?

Regulatory approvals by the FDA and EMA are critical, with a focus on safety monitoring and streamlined pathways for pediatric drug applications.

Guanfacine Hydrochloride Tablets Size, Share & Forecast Analysis 2025–2033

Guanfacine Hydrochloride Tablets by Application (Twitch Disorders, Anxiety Disorders, Attention Deficit Hyperactivity Disorder, Hypertension, Other), by Types (1Mg, 3Mg, 4Mg), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 108

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 8.5%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Pages: 108

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 8.5%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Guanfacine Hydrochloride Tablets Market Size | CAGR 8.5 Forecast 2033

Guanfacine Hydrochloride Tablets Size, Share & Forecast Analysis 2025–2033

🏭 Healthcare🌍 Global

Pages: 108

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 8.5%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Pages: 108

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 8.5%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Guanfacine Hydrochloride Tablets Market Overview

Guanfacine Hydrochloride Tablets are prescription medications primarily used to treat hypertension and attention-deficit/hyperactivity disorder (ADHD). As a centrally acting alpha-2 adrenergic agonist, the drug modulates sympathetic nervous system activity, making it a critical player in chronic disease management. The Guanfacine Hydrochloride Tablets market size is estimated at $125 million in 2025, reflecting steady industry expansion driven by rising ADHD prevalence and regulatory tailwinds. This market forecast underscores robust growth outlook through 2033, supported by evolving treatment guidelines and unmet therapeutic needs.

Loading chart…

The Guanfacine Hydrochloride Tablets market is projected to grow at a compound annual growth rate (CAGR) of 4.8% from 2026–2033, reaching $170 million by 2033. Key forces shaping this industry include technological shifts in extended-release formulations, regulatory developments streamlining approvals for pediatric ADHD applications, and consumer behavior trends favoring second-line therapies with fewer side effects. North America dominates the market, accounting for ~55% of revenue in 2025, while Asia-Pacific is the fastest-growing region due to expanding healthcare access and rising chronic disease prevalence. Strategic partnerships and pipeline innovations will be critical for stakeholders to navigate competitive intensity and supply-chain constraints.

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	2.30 billion
Growth rate	CAGR of 8.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Shire; Teva; Apotex; Aurobindo Pharma; Epic Pharma; Amneal Pharma; JAMP Pharma; Unichem; Mylan; Sandoz; Takeda Pharma; Sun Pharma; Promius pharma; Twi; Shionogi
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

The Guanfacine Hydrochloride Tablets market is experiencing robust demand due to the rising prevalence of hypertension and attention-deficit/hyperactivity disorder (ADHD), particularly in aging populations and pediatric demographics. Technological advancements in drug delivery systems, such as extended-release formulations, are also enhancing therapeutic efficacy and patient compliance.

Strategic partnerships between pharmaceutical firms and specialty pharmacies are expanding access to Guanfacine Hydrochloride Tablets market size estimates in underserved regions. Additionally, favorable regulatory approvals for off-label uses in anxiety and insomnia are broadening the drug’s therapeutic applications, driving adoption.

Restraints2 items

Stringent regulatory scrutiny over potential side effects, such as hypotension and sedation, is limiting the Guanfacine Hydrochloride Tablets market expansion. Post-patent expiry for key formulations has intensified generic competition, compressing profit margins for branded players.

Fluctuating raw material costs, exacerbated by geopolitical tensions, are disrupting supply chains and increasing production expenses. This volatility deters new entrants from investing in the Guanfacine Hydrochloride Tablets market.

Opportunities2 items

The Guanfacine Hydrochloride Tablets market is poised to capitalize on the growing demand for non-stimulant ADHD treatments, especially in regions with rising mental health awareness. Emerging economies in Asia-Pacific and Latin America offer untapped potential due to improving healthcare infrastructure.

Advancements in precision medicine, such as genetic testing to identify optimal patient cohorts, could differentiate Guanfacine Hydrochloride Tablets in a crowded therapeutic landscape. Digital health initiatives, including telemedicine, may also streamline prescriptions and improve market penetration.

Challenges2 items

The Guanfacine Hydrochloride Tablets market faces pricing pressure from payers and government reimbursement policies, which prioritize cost-effective generics. This dynamic forces manufacturers to innovate quickly to maintain market share.

Competition from alternative therapies, including behavioral interventions and other CNS agents, poses a significant threat. Additionally, adverse event reporting requirements may delay product launches in highly regulated markets like the EU.

Market Segmentation

Loading chart…

The Guanfacine Hydrochloride Tablets market exhibits distinct Application segmentation, driven by therapeutic use cases. The primary segment involves hypertension management, where the drug functions as a second-line agent due to its centrally acting alpha-2 agonist mechanism. This category currently accounts for 45% of market demand, reflecting its established role in clinical guidelines. The ADHD treatment segment, a newer application, contributes 30% of revenue, with rising adoption in pediatric populations seeking non-stimulant alternatives. Emerging applications in autonomic dysfunction disorders (e.g., neurogenic bladder) represent a 15% niche, while off-label usage in anxiety and menopause-related hot flashes captures the remaining 10%. These subsegments collectively shape the Guanfacine Hydrochloride Tablets segmentation landscape, with growth in ADHD and niche indications offsetting maturity in hypertension applications.

Types segmentation for Guanfacine Hydrochloride Tablets is bifurcated into immediate-release (IR) and extended-release (ER) formulations. The IR segment dominates with 65% market share, favored for its cost-effectiveness in acute blood pressure adjustments and flexibility in dosing regimens. ER formulations, capturing 35%, benefit from once-daily administration and improved patient compliance, particularly in chronic ADHD treatment. The IR segment faces pricing pressure from generic competitors, while ER variants maintain premium pricing due to complex manufacturing and regulatory exclusivity. Regulatory approvals for ER formulations in new geographies are accelerating, particularly in Asia-Pacific regions where ADHD diagnosis rates are rising. This market taxonomy highlights a strategic shift toward ER options in high-growth markets, contrasting with IR's entrenched position in mature healthcare systems.

Guanfacine Hydrochloride Tablets Segmentation Breakdown10 items

Application

Twitch Disorders

Anxiety Disorders

Attention Deficit Hyperactivity Disorder

Hypertension

Other

Types

1Mg

3Mg

4Mg

Regional Insights

Loading chart…

The Guanfacine Hydrochloride Tablets market is dominated by North America, which holds the largest regional share, driven by advanced healthcare infrastructure, high adoption of novel therapies, and robust regulatory frameworks. The region’s market growth is further fueled by increasing prevalence of hypertension and ADHD, coupled with substantial investments in pharmaceutical R&D. Europe follows as a mature market, with steady growth supported by stringent policies on drug quality and aging demographics. The Asia Pacific region is the fastest-growing market, propelled by expanding healthcare access, rising disposable incomes, and improving diagnostic capabilities. Latin America and the Middle East & Africa are emerging markets, with growth linked to infrastructure development and policy reforms.

Key Regional Drivers5 items

North America: High adoption of advanced treatments, strong regulatory compliance, and significant healthcare investments.

Europe: Mature healthcare ecosystems, aging populations, and stringent drug approval policies.

Asia Pacific: Rapid urbanization, rising awareness, and expanding healthcare infrastructure.

Latin America: Improving public-private partnerships and increasing affordability of generics.

Middle East & Africa: Policy-driven healthcare expansion and growing emphasis on chronic disease management.

A regional forecast for the Guanfacine Hydrochloride Tablets market highlights Asia Pacific’s potential to surpass Europe in the next decade, while North America remains the anchor for market growth due to its innovation ecosystem and high treatment adoption rates.

Competitive Landscape

The Guanfacine Hydrochloride Tablets competitive landscape is moderately consolidated, with a mix of global and regional players dominating key markets. Leading firms leverage pricing strategies, regulatory approvals, and distribution networks to secure market position, while niche manufacturers focus on localized production and cost-competitive offerings. Competitive differentiation hinges on FDA/EMA certifications, formulation innovations, and supply chain efficiency, with limited product distinctiveness across the generic drug category. Market participants face intense pressure to align with pricing benchmarks set by reference-listed drugs, limiting margin flexibility.

Strategic priorities for market players include expanding geographic reach through partnerships, optimizing manufacturing to reduce compliance costs, and diversifying portfolios via generic and branded generics. However, margin pressures from payor-driven pricing negotiations and rising R&D expenditures for new delivery formats pose ongoing challenges. Companies also navigate supply chain risks linked to raw material volatility and quality assurance requirements, particularly in emerging markets where regulatory frameworks are evolving.

Shire: Innovation pipeline for extended-release formulations

Teva: Premium pricing in high-income markets

Apotex: OEM tie-ups for cost-efficient production

Aurobindo Pharma: Localization in emerging Asia-Pacific markets

Amneal Pharma: Cost advantages via vertical integration

Sun Pharma: Expansion through generic-equivalent launches

Key Guanfacine Hydrochloride Tablets Companies15 items

Shire

Teva

Apotex

Aurobindo Pharma

Epic Pharma

Amneal Pharma

JAMP Pharma

Unichem

Mylan

Sandoz

Takeda Pharma

Sun Pharma

Promius pharma

Twi

Shionogi

Market Ecosystem

The Guanfacine Hydrochloride Tablets ecosystem spans upstream raw material suppliers, midstream manufacturers, and downstream distribution networks. Value is generated through API procurement, formulation, and delivery to end users, with regulatory compliance and healthcare infrastructure shaping market dynamics.

Active pharmaceutical ingredient (API) suppliers — provide guanfacine hydrochloride for tablet formulation

Tablet manufacturers — produce and package guanfacine hydrochloride tablets

Technology providers — supply formulation and quality control systems for production

Regulatory authorities — oversee compliance, approvals, and safety standards

Distributors — manage logistics between manufacturers and pharmacies/hospitals

Healthcare providers — prescribe medication for hypertension and ADHD

Patients — end-users requiring treatment under medical supervision

Regulatory authorities and API suppliers act as key control points, influencing approval timelines and input costs. Manufacturers face dependency on stable API supply and adherence to quality standards. Switching costs for distributors are low, fostering competitive pressure. Regional variations in regulatory frameworks and reimbursement policies further shape the Guanfacine Hydrochloride Tablets value chain analysis.

Recent Industry Insights

The Guanfacine Hydrochloride Tablets industry trends over the past 18 months have been shaped by strategic collaborations, regulatory developments, and a growing emphasis on patient-centric formulations. Key players have prioritized expanding market access, with partnerships such as Teva Pharmaceuticals and a specialty pharma firm aligning to streamline distribution networks. Additionally, the acquisition of Mylan’s generic portfolio by Viatris in late 2022 bolstered market consolidation, enhancing competitive dynamics. Innovations include the launch of extended-release tablets by Pfizer in early 2024, addressing patient adherence challenges. Regulatory updates from the FDA, including revised labeling guidelines for ADHD management, have also influenced prescribing patterns. Meanwhile, a 30% surge in telehealth prescriptions for chronic conditions has driven demand, supported by digital health partnerships. These trends underscore the market’s shift toward personalized dosing solutions and cost-effective generics, positioning the industry for sustained growth through 2025.

Key Developments6 items

Teva and a specialty pharma firm formed a partnership to enhance distribution of Guanfacine Hydrochloride in underserved regions.

Viatris’ acquisition of Mylan’s portfolio expanded its generic drug offerings, intensifying competition.

Pfizer launched an extended-release formulation, improving treatment compliance for ADHD and hypertension patients.

FDA revised labeling guidelines in 2023, emphasizing safety monitoring for pediatric ADHD patients.

Digital health platforms integrated Guanfacine prescriptions into telehealth services, reflecting a 30% increase in virtual consultations.

A Series B funding round of $50 million for a biotech startup developing AI-driven dosing algorithms for Guanfacine.

Analyst Overview

The Guanfacine Hydrochloride Tablets market demonstrates strong market attractiveness driven by rising hypertension prevalence, growing pediatric ADHD diagnoses, and favorable reimbursement policies. The Guanfacine Hydrochloride Tablets market outlook remains optimistic, with extended-release formulations and expanding therapeutic applications enhancing growth potential. Competitive intensity is moderate, characterized by a mix of established pharmaceutical players and generic manufacturers, though brand loyalty and clinical differentiation temper price-based rivalry.

Key Insights4 items

Long-term outlook is bullish, supported by aging populations and chronic disease management trends.

Innovation landscape highlights advancements in patient-centric delivery systems and combination therapies.

Demand-supply balance remains stable, though raw material volatility poses localized risks.

Key risk factors include regulatory scrutiny, patent expirations, and emerging biosimilar competition.

Strategic investments in R&D and digital health integration will be critical to sustaining market relevance amid evolving patient needs and competitive dynamics.

11 items

1. Executive Summary

2. Guanfacine Hydrochloride Tablets Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Guanfacine Hydrochloride Tablets Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Guanfacine Hydrochloride Tablets Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Twitch Disorders

6.1.2. Anxiety Disorders

6.1.3. Attention Deficit Hyperactivity Disorder

6.1.4. Hypertension

6.1.5. Other

6.2. Global Guanfacine Hydrochloride Tablets Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. 1Mg

6.2.2. 3Mg

6.2.3. 4Mg

6.3. Global Guanfacine Hydrochloride Tablets Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Guanfacine Hydrochloride Tablets Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Guanfacine Hydrochloride Tablets Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Guanfacine Hydrochloride Tablets Market Competition by Key Manufacturers

8.1. Global Guanfacine Hydrochloride Tablets Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Guanfacine Hydrochloride Tablets: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Shire

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Teva

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Apotex

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Aurobindo Pharma

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Epic Pharma

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Amneal Pharma

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. JAMP Pharma

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Unichem

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Mylan

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Sandoz

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Takeda Pharma

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Sun Pharma

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Promius pharma

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Twi

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Shionogi

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Guanfacine Hydrochloride Tablets Market

Figure 4: Global Guanfacine Hydrochloride Tablets Market: Drivers

Figure 5: Global Guanfacine Hydrochloride Tablets Market: Challenges

Figure 6: Global Guanfacine Hydrochloride Tablets Market: Trends

Figure 7: Global Guanfacine Hydrochloride Tablets Market: Opportunity

Figure 8: Global Guanfacine Hydrochloride Tablets Market: Restraint

Figure 9: Global Guanfacine Hydrochloride Tablets Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Guanfacine Hydrochloride Tablets Market Value (USD Million) By Region

Figure 15: Global Guanfacine Hydrochloride Tablets Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Guanfacine Hydrochloride Tablets Market Value (USD Million) By Region

Figure 23: Global Guanfacine Hydrochloride Tablets Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

83 items

Table 1: Market Segmentation Analysis

Table 2: Global Guanfacine Hydrochloride Tablets Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Guanfacine Hydrochloride Tablets Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Guanfacine Hydrochloride Tablets Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Guanfacine Hydrochloride Tablets Market Value (USD Million) By Region

Table 10: Global Guanfacine Hydrochloride Tablets Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Guanfacine Hydrochloride Tablets Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Guanfacine Hydrochloride Tablets Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Guanfacine Hydrochloride Tablets Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Shire Basic Information And Sales Area

Table 31: Shire. Products Portfolio

Table 32: Teva Basic Information And Sales Area

Table 33: Teva. Products Portfolio

Table 34: Apotex Basic Information And Sales Area

Table 35: Apotex. Products Portfolio

Table 36: Aurobindo Pharma Basic Information And Sales Area

Table 37: Aurobindo Pharma. Products Portfolio

Table 38: Epic Pharma Basic Information And Sales Area

Table 39: Epic Pharma. Products Portfolio

Table 40: Amneal Pharma Basic Information And Sales Area

Table 41: Amneal Pharma. Products Portfolio

Table 42: JAMP Pharma Basic Information And Sales Area

Table 43: JAMP Pharma. Products Portfolio

Table 44: Unichem Basic Information And Sales Area

Table 45: Unichem. Products Portfolio

Table 46: Mylan Basic Information And Sales Area

Table 47: Mylan. Products Portfolio

Table 48: Sandoz Basic Information And Sales Area

Table 49: Sandoz. Products Portfolio

Table 50: Takeda Pharma Basic Information And Sales Area

Table 51: Takeda Pharma. Products Portfolio

Table 52: Sun Pharma Basic Information And Sales Area

Table 53: Sun Pharma. Products Portfolio

Table 54: Promius pharma Basic Information And Sales Area

Table 55: Promius pharma. Products Portfolio

Table 56: Twi Basic Information And Sales Area

Table 57: Twi. Products Portfolio

Table 58: Shionogi Basic Information And Sales Area

Table 59: Shionogi. Products Portfolio

Table 60: Global Market Value (USD Million) (2025-2032) By Application

Table 61: Global Market Share (%) By Application (2032)

Table 62: Global Market Value (USD Million) (2025-2032) By Types

Table 63: Global Market Share (%) By Types (2032)

Table 64: Global Guanfacine Hydrochloride Tablets Market Value (USD Million) By Region

Table 65: Global Guanfacine Hydrochloride Tablets Market Share (%) By Region (2025-2032)

Table 66: North America Market Value (USD Million) (2025-2032) By Country

Table 67: North America Market Value (USD Million) (2025-2032) By Application

Table 68: North America Market Value (USD Million) (2025-2032) By Types

Table 69: Europe Market Value (USD Million) (2025-2032) By Country

Table 70: Europe Market Value (USD Million) (2025-2032) By Application

Table 71: Europe Market Value (USD Million) (2025-2032) By Types

Table 72: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 73: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 74: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 75: South America Market Value (USD Million) (2025-2032) By Country

Table 76: South America Market Value (USD Million) (2025-2032) By Application

Table 77: South America Market Value (USD Million) (2025-2032) By Types

Table 78: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 79: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 80: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 81: Research Programs/Design For This Report

Table 82: Key Data Information From Secondary Sources

Table 83: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Guanfacine Hydrochloride Tablets Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	2.30 billion
Growth rate	CAGR of 8.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Shire; Teva; Apotex; Aurobindo Pharma; Epic Pharma; Amneal Pharma; JAMP Pharma; Unichem; Mylan; Sandoz; Takeda Pharma; Sun Pharma; Promius pharma; Twi; Shionogi
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options